Objective
to compare the clinical outcomes of ultra-thin strut stent (Supraflex Cruz) with Thin-strut stent (Tansei) implantation in patients at high risk (HBR) and short DAPT after stenting
Study
open-label, multicentre randomised non-inferiority trial (margin 4.0%)
Population
HBR following ARC HBR criteria
Endpoints
net adverse clinical events (MACE): cardiovascular death, MI,TV-revascularisation, stroke and major bleeding at 1 year
Conclusion
among patients at HBR with short DAPT post-stenting, ultra-thin strut stents were non-inferior compared to thin-strut stents
Smits et al. Circulation Cardiovascular Interventions. 2024;17:e014042.
